Emergency: 911 Crisis: call or text 988 PA DDAP: 1-800-662-4357 PA 211: 2-1-1
24/7 Placement Advisors — Call (215) 792-4574

Medication-Assisted Treatment (MAT) in Philadelphia | Anchor Point Addiction Center

The FDA has approved three medications for opioid use disorder: buprenorphine, methadone and naltrexone (FDA). In Philadelphia, where fentanyl was detected in 93% of opioid-involved overdose deaths in 2024 (PDPH), MAT is a core part of opioid treatment.

What Is Medication-Assisted Treatment?

Medication-Assisted Treatment (MAT) combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders — particularly opioid use disorder (OUD). The three FDA-approved medications for OUD (FDA) are: buprenorphine (brand names include Suboxone), which reduces withdrawal symptoms and cravings while blocking the effects of other opioids; methadone, a full opioid agonist with a long track record in OUD treatment; and naltrexone (brand name Vivitrol), an opioid antagonist that blocks opioid effects entirely, used after detox is complete.

Does MAT Work for Fentanyl Dependence?

Yes. MAT is highly effective for fentanyl use disorder. Buprenorphine and methadone have strong evidence for reducing overdose deaths, reducing illicit drug use, improving treatment retention, and improving social functioning. For people in Philadelphia dealing with fentanyl dependence — especially where xylazine or medetomidine are also involved — MAT initiation in an inpatient setting allows for medically supervised stabilization before transitioning to outpatient MAT maintenance.

Ready to Talk? Call (215) 792-4574 — Available 24/7.

Free insurance verification in minutes. We tell you what your plan covers in one call. Confidential, no obligation.

(215) 792-4574

Frequently Asked Questions

Is Suboxone given in inpatient rehab?

Yes. Many inpatient programs initiate buprenorphine (Suboxone) during the detox phase and continue MAT throughout the residential stay. On discharge, patients are typically connected with an outpatient MAT provider for long-term maintenance. MAT dramatically reduces the risk of relapse and overdose death after discharge.

Call Now